The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and
possesses unique characteristics that make the delivery of drugs to the brain a great …

Antimicrobial drugs are key tools to prevent and treat bacterial infections. Despite the early
success of antibiotics, the current treatment of bacterial infections faces serious challenges …

Glioblastomas (GBMs) are highly aggressive brain tumors with a very grim prognosis even
after multi-modal therapeutic regimens. Conventional chemotherapeutic agents frequently …

The aggregation of amyloid-β peptide (Aβ) has been linked to the formation of neuritic
plaques, which are pathological hallmarks of Alzheimer's disease (AD). Various natural …

Alzheimer's Disease (AD) is a neurodegenerative disorder related with the increase of age
and it is the main cause of dementia in the world. AD affects cognitive functions, such as …

The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …

Quercetin was encapsulated in lipid nanoparticles (SLN and NLC) to take advantage of its
neuroprotective properties in Alzheimer's disease. The nanoparticles were functionalized …

Nanoparticles, especially liposomes, have gained prominence in the field of drug delivery
for the treatment of human diseases, particularly cancer; they provide several advantages …

Nanotechnology profoundly affects the advancement of medicine. Limitations in diagnosing
and treating cancer and chronic diseases promote the growth of nanomedicine. However …